301 related articles for article (PubMed ID: 31494078)
21. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
[TBL] [Abstract][Full Text] [Related]
22. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
Roberts AW; Huang D
Clin Pharmacol Ther; 2017 Jan; 101(1):89-98. PubMed ID: 27806433
[TBL] [Abstract][Full Text] [Related]
23. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
[TBL] [Abstract][Full Text] [Related]
24. Targeting Bcl-2 for the treatment of multiple myeloma.
Touzeau C; Maciag P; Amiot M; Moreau P
Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
[TBL] [Abstract][Full Text] [Related]
25. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
[TBL] [Abstract][Full Text] [Related]
26. Peptide screening to knockdown Bcl-2's anti-apoptotic activity: implications in cancer treatment.
Raghav PK; Verma YK; Gangenahalli GU
Int J Biol Macromol; 2012 Apr; 50(3):796-814. PubMed ID: 22155216
[TBL] [Abstract][Full Text] [Related]
27. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise.
Sarosiek KA; Letai A
FEBS J; 2016 Oct; 283(19):3523-3533. PubMed ID: 26996748
[TBL] [Abstract][Full Text] [Related]
28. Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737.
Stauffer SR
Curr Top Med Chem; 2007; 7(10):961-5. PubMed ID: 17508927
[TBL] [Abstract][Full Text] [Related]
29. The novel small molecular BH3 mimetics SM3 and its regulation of cell apoptosis and autophagy.
Wang Y; Fan S; Li X; Xiaokaiti Y; Pan Y; Tie L; Li X
Biochem Biophys Res Commun; 2019 Sep; 517(1):15-22. PubMed ID: 31303271
[TBL] [Abstract][Full Text] [Related]
30. Development of 3-phenyl-N-(2-(3-phenylureido)ethyl)-thiophene-2-sulfonamide compounds as inhibitors of antiapoptotic Bcl-2 family proteins.
Yang C; Chen S; Zhou M; Li Y; Li Y; Zhang Z; Liu Z; Ba Q; Li J; Wang H; Yan X; Ma D; Wang R
ChemMedChem; 2014 Jul; 9(7):1436-52. PubMed ID: 24782462
[TBL] [Abstract][Full Text] [Related]
31. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
[TBL] [Abstract][Full Text] [Related]
32. Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.
Vogler M; Walter HS; Dyer MJS
Br J Haematol; 2017 Aug; 178(3):364-379. PubMed ID: 28449207
[TBL] [Abstract][Full Text] [Related]
33. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
[TBL] [Abstract][Full Text] [Related]
34. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.
Azmi AS; Mohammad RM
J Cell Physiol; 2009 Jan; 218(1):13-21. PubMed ID: 18767026
[TBL] [Abstract][Full Text] [Related]
35. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.
Vogler M; Dinsdale D; Dyer MJ; Cohen GM
Cell Death Differ; 2009 Mar; 16(3):360-7. PubMed ID: 18806758
[TBL] [Abstract][Full Text] [Related]
36. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma.
Turner BC; Eves T; Refaeli Y
DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880
[TBL] [Abstract][Full Text] [Related]
37. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Besbes S; Pocard M; Mirshahi M; Billard C
Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
[TBL] [Abstract][Full Text] [Related]
38. PMCA2 silencing potentiates MDA-MB-231 breast cancer cell death initiated with the Bcl-2 inhibitor ABT-263.
Curry M; Roberts-Thomson SJ; Monteith GR
Biochem Biophys Res Commun; 2016 Sep; 478(4):1792-7. PubMed ID: 27613092
[TBL] [Abstract][Full Text] [Related]
39. Targeting cancer's Achilles' heel: role of BCL-2 inhibitors in cellular senescence and apoptosis.
Anantram A; Degani M
Future Med Chem; 2019 Sep; 11(17):2287-2312. PubMed ID: 31581912
[TBL] [Abstract][Full Text] [Related]
40. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A
Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
